Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 213

Results For "clinical"

2937 News Found

Genome Insight draws US $ 23 million in Series B Funding
Startup | May 01, 2022

Genome Insight draws US $ 23 million in Series B Funding

Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application


BeiGene to open new site at Princeton, New Jersey
Biotech | May 01, 2022

BeiGene to open new site at Princeton, New Jersey

Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines


USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
Drug Approval | May 01, 2022

USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis

The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases


Inmagene receives USFDA's IND clearance for ox40 antagonist
Biotech | May 01, 2022

Inmagene receives USFDA's IND clearance for ox40 antagonist

The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients


ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis
Public Health | May 01, 2022

ASPIRE 2022 Congress: Recognising the 'tip of the iceberg' in the complex and chronic effects of endometriosis

It affects up to 10 per cent of women of reproductive age around the world


Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
Biotech | April 29, 2022

Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec

In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec


Ultomiris approved in the US for adults with generalised myasthenia gravis
Drug Approval | April 29, 2022

Ultomiris approved in the US for adults with generalised myasthenia gravis

Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks


Philips and Prisma Health sign multi-year, long-term strategic partnership
Digitisation | April 29, 2022

Philips and Prisma Health sign multi-year, long-term strategic partnership

South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim


Camzyos is the first and only USFDA-approved cardiac myosin inhibitor
Biotech | April 29, 2022

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo


Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Biotech | April 29, 2022

Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity

Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study